Comparative evaluation of lumpy skin disease virus-based live atenuated vaccines
| dc.contributor.author | Haegeman, Andy | |
| dc.contributor.author | De Leeuw, Ilse | |
| dc.contributor.author | Mostin, Laurent | |
| dc.contributor.author | Van Campe, Willem | |
| dc.contributor.author | Aerts, Laetitia | |
| dc.contributor.author | Venter, Estelle Hildegard | |
| dc.contributor.author | Tuppurainen, Eeva | |
| dc.contributor.author | Saegerman, Claude | |
| dc.contributor.author | De Clercq, Kris | |
| dc.date.accessioned | 2022-05-05T06:10:44Z | |
| dc.date.available | 2022-05-05T06:10:44Z | |
| dc.date.issued | 2021-05 | |
| dc.description.abstract | Vaccines form the cornerstone of any control, eradication and preventative strategy and this is no different for lumpy skin disease. However, the usefulness of a vaccine is determined by a multiplicity of factors which include stability, efficiency, safety and ease of use, to name a few. Although the vaccination campaign in the Balkans against lumpy skin disease virus (LSDV) was successful and has been implemented with success in the past in other countries, data of vaccine failure have also been reported. It was therefore the purpose of this study to compare five homologous live attenuated LSDV vaccines (LSDV LAV) in a standardized setting. All five LSDV LAVs studied were able to protect against a challenge with virulent LSDV. Aside from small differences in serological responses, important differences were seen in side effects such as a local reaction and a Neethling response upon vaccination between the analyzed vaccines. These observations can have important implications in the applicability in the field for some of these LSDV LAVs. | en_US |
| dc.description.department | Veterinary Tropical Diseases | en_US |
| dc.description.librarian | pm2022 | en_US |
| dc.description.sponsorship | The Bill & Melinda Gates Foundation, the GALVmed project Nr CAO-R34A0856 on lumpy skin disease and the Belgian Federal Public Service of Health, Food Chain Safety and Environment through the contract RT 15/3 (LUMPY SKIN 1). | en_US |
| dc.description.uri | http://www.mdpi.com/journal/vaccines | en_US |
| dc.identifier.citation | Haegeman, A.; De Leeuw, I.; Mostin, L.; Campe, W.V.; Aerts, L.; Venter, E.; Tuppurainen, E.; Saegerman, C.; De Clercq, K. Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines. Vaccines 2021, 9, 473. https://doi.org/10.3390/vaccines9050473. | en_US |
| dc.identifier.issn | 2076-393X (online) | |
| dc.identifier.other | 10.3390/ vaccines9050473 | |
| dc.identifier.uri | https://repository.up.ac.za/handle/2263/85069 | |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI | en_US |
| dc.rights | © 2021 by the authors. Licensee: MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. | en_US |
| dc.subject | Vaccine evaluation | en_US |
| dc.subject | Live attenuated vaccines | en_US |
| dc.subject | Lumpy skin disease vaccine | en_US |
| dc.subject | Lumpy skin disease virus (LSDV) | en_US |
| dc.title | Comparative evaluation of lumpy skin disease virus-based live atenuated vaccines | en_US |
| dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.75 KB
- Format:
- Item-specific license agreed upon to submission
- Description:
